News

The Phase III registration program for DM-5689 in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. The treatment duration of the

The trial included four groups of 10 subjects each to assess the safety and tolerability of escalating doses of RGN-352 injected daily into the blood stream over a

The company has also announced that Joel Fleishman will retire from the board in May 2009. For the past six years Mr Sununu served as a US senator

The payment to Power Medical Interventions (PMI) was made in connection with the license and development agreement signed in September 2008 and is related to a novel surgical

Dr Fuchs will replace longtime BioMarin chief medical officer, Emil Kakkis. Dr Fuchs most recently served as executive vice president and chief medical officer of Onyx Pharmaceuticals. Dr

Sigal, the company’s executive vice president, chief scientific officer and president, research & development, oversees the company’s research, discovery, and development functions. Huet was promoted to executive vice

He will continue to report to James M. Cornelius, chairman and chief executive officer. “Lamberto’s leadership has been an integral part of our recent global commercial success, and

OSA is a condition that is characterized by periods of apnea during sleep. Apnea is defined as a temporary absence in breathing. Persons with OSA usually snore; however,

In spite of the current macroeconomic environment, Exiqon expects 2009 to be another year with strong organic growth. Product demand remains strong and we will continue to invest